AbbVie's RINVOQ Wins European Commission Approval For Non-Segmental Vitiligo, First Systemic Medication Approved In EU For This Condition
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV)The approval is supported by data from the Phase 3 Viti-Up clinical
AbbVie got approval in Europe for a new medicine called RINVOQ that treats a skin condition called vitiligo—it's the first pill-form medicine allowed there for this. This is good news because it shows the company's medicine works and could help new patients, though we don't know yet how many people will actually use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.